AYTU Bets on Antidepressant EXXUA Amidst $13.6M Loss

TL;DR

**AYTU is making a high-stakes bet on EXXUA to turn around its financials, but profitability is still a distant hope.**

AI Summary

AYTU BIOPHARMA, INC. reported a net loss of $13.6 million for the fiscal year ended June 30, 2025, contributing to an accumulated deficit of $333.5 million. Despite the loss, the company achieved net revenue of $66.4 million, driven by strong performance in its ADHD Portfolio, which generated $57.6 million, its second-highest historical revenue. The Pediatric Portfolio also saw significant growth, increasing 20% from fiscal 2024 to $8.8 million. A key strategic move was the June 2025 Exclusive Commercialization Agreement with Fabre-Kramer Holdings, Inc. for EXXUA (gepirone), a novel antidepressant, which AYTU anticipates launching in Q4 2025 to target the over $22 billion U.S. MDD market. The company also completed the wind-down and divestiture of its Consumer Health business in Q1 2025 and transferred manufacturing of its ADHD products to a U.S.-based third-party to improve profitability. Furthermore, AYTU terminated its AR101 development program and related agreements on August 5, 2025, to focus resources on revenue-generating products.

Why It Matters

AYTU's strategic pivot towards commercializing EXXUA in the $22 billion MDD market could be a game-changer, potentially offering investors a path to profitability after years of losses. For patients, EXXUA's unique profile, lacking sexual dysfunction warnings common with SSRIs, could significantly improve treatment adherence and quality of life. This move also intensifies competition in the antidepressant space, pushing other pharmaceutical companies to innovate. Employees will see a renewed focus on commercialization, while the divestiture of unprofitable segments signals a leaner, more focused operational strategy, aiming for positive operating cash flows.

Risk Assessment

Risk Level: high — AYTU has an accumulated deficit of $333.5 million as of June 30, 2025, and incurred a net loss of $13.6 million for fiscal 2025, indicating a history of unprofitability. The company explicitly states it 'may need to raise additional funding,' which could dilute existing shareholders, and is 'heavily dependent on the commercial success of our commercial products,' particularly the upcoming EXXUA launch, which faces a highly competitive $22 billion market.

Analyst Insight

Investors should closely monitor the Q4 2025 launch of EXXUA and its initial sales performance, as this product is positioned as a major growth catalyst. Given the high accumulated deficit and ongoing losses, a 'wait and see' approach is prudent to assess if EXXUA can generate sufficient revenue to offset operational costs and move the company towards profitability.

Financial Highlights

debt To Equity

N/A

revenue

$66.4 million

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$13.6 million

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $13.6 million — Net Loss (for the year ended June 30, 2025, indicating continued unprofitability.)
• $333.5 million — Accumulated Deficit (as of June 30, 2025, highlighting significant historical losses.)
• $66.4 million — Net Revenue (for fiscal 2025, driven by prescription product sales.)
• $57.6 million — ADHD Portfolio Net Revenue (second highest in company history for fiscal 2025, demonstrating strong product performance.)
• $8.8 million — Pediatric Portfolio Net Revenue (a 20% increase from fiscal 2024, reflecting positive growth.)
• $22 billion — U.S. MDD Market Size (target market for EXXUA, representing a significant opportunity.)
• 9,911,913 — Shares of Common Stock Outstanding (as of September 15, 2025.)
• $7,238,109 — Market Value of Non-Affiliate Common Stock (as of December 31, 2024, based on a $1.70 share price.)
• 20% — Pediatric Portfolio Growth (increase from fiscal 2024 to fiscal 2025.)
• Q4 2025 — Anticipated EXXUA Launch (critical period for new product commercialization.)

Key Players & Entities

• AYTU BIOPHARMA, INC. (company) — registrant
• Fabre-Kramer Holdings, Inc. (company) — partner for EXXUA commercialization
• EXXUA (company) — novel first-in-class selective serotonin 5HT1a receptor agonist
• Nasdaq Capital Market (regulator) — exchange where AYTU common stock trades
• EnzCo, LLC (company) — party in AR101 asset transfer
• Rumpus VEDS LLC (company) — party in AR101 asset transfer
• U.S. Food and Drug Administration (regulator) — approved EXXUA
• Adzenys XR-ODT (company) — ADHD product
• Cotempla XR-ODT (company) — ADHD product
• Karbinal ER (company) — Pediatric Portfolio product

FAQ

Risk Factors

• Accumulated Deficit and Net Losses [high — financial]: The company has an accumulated deficit of $333.5 million as of June 30, 2025, and reported a net loss of $13.6 million for the fiscal year ended June 30, 2025. This indicates a history of unprofitability and reliance on external funding to sustain operations.
• FDA Approval and Commercialization Risks [high — regulatory]: The successful commercialization of EXXUA (gepirone) is critical, with an anticipated launch in Q4 2025. Any delays in market penetration, unexpected side effects post-launch, or competitive pressures in the $22 billion U.S. MDD market could significantly impact revenue and profitability.
• Dependence on Third-Party Manufacturing [medium — operational]: The transfer of manufacturing for ADHD products to a U.S.-based third-party aims to improve profitability. However, this introduces operational risks related to supply chain reliability, quality control, and potential disruptions from the third-party provider.
• Reliance on New Product Success [high — financial]: The company's strategy heavily relies on the success of EXXUA, a novel antidepressant. Failure to capture significant market share in the competitive MDD market could hinder the company's path to profitability and impact its financial stability.
• Termination of Development Programs [medium — operational]: The termination of the AR101 development program on August 5, 2025, indicates a strategic shift but also highlights the risks associated with R&D investments and the potential for unrecoverable expenses if programs do not yield expected results.

Industry Context

The pharmaceutical industry, particularly the central nervous system (CNS) therapeutics market, is highly competitive and R&D intensive. Companies are focused on developing novel treatments for conditions like Major Depressive Disorder (MDD) where significant unmet needs persist due to side effects of existing therapies. The market for MDD treatments is substantial, exceeding $22 billion in the U.S., attracting both large pharmaceutical players and smaller biotech firms seeking to innovate.

Regulatory Implications

The FDA approval of EXXUA is a significant milestone, but ongoing regulatory compliance is crucial. Post-market surveillance for safety and efficacy, adherence to manufacturing standards, and accurate marketing claims are critical to avoid regulatory actions. Any adverse events or issues with product quality could lead to warnings, recalls, or market withdrawal.

What Investors Should Do

1. Monitor EXXUA launch performance closely.
2. Assess the impact of the Consumer Health divestiture and manufacturing transfer.
3. Evaluate the company's cash burn rate and future funding needs.
4. Analyze competitive landscape for MDD treatments.

Key Dates

• 2025-06-01: Exclusive Commercialization Agreement with Fabre-Kramer for EXXUA — Secured rights to commercialize a novel antidepressant, EXXUA, targeting a significant market opportunity in MDD.
• 2025-03-01: Completion of Consumer Health business wind-down and divestiture — Streamlined business operations by exiting a non-core segment, allowing focus on prescription therapeutics.
• 2025-01-01: Transfer of manufacturing for ADHD products to a U.S.-based third-party — Aims to improve profitability and operational efficiency for key revenue-generating products.
• 2025-08-05: Termination of AR101 development program — Reallocation of resources to focus on revenue-generating products and strategic commercialization efforts.
• 2025-10-01: Anticipated EXXUA launch — Marks the introduction of a key growth catalyst product into the large U.S. MDD market.

Glossary

MDD

Major Depressive Disorder, a common and serious mood disorder that causes persistent feeling of sadness and loss of interest. (EXXUA is approved for the treatment of MDD, a market estimated at over $22 billion in the U.S.)

5HT1a receptor agonist

A substance that binds to and activates the 5HT1a serotonin receptor, influencing mood and emotion. (EXXUA's mechanism of action is based on its selective binding to these receptors, differentiating it from other antidepressants.)

SSRI

Selective Serotonin Reuptake Inhibitor, a common class of antidepressants that work by increasing the levels of serotonin in the brain. (EXXUA is not an SSRI and does not carry the associated label warnings for sexual dysfunction, a key differentiator.)

Accumulated Deficit

The total cumulative net losses of a company since its inception, minus any cumulative net income. (Aytu BioPharma has a significant accumulated deficit of $333.5 million, indicating substantial historical unprofitability.)

Year-Over-Year Comparison

The company reported a net loss of $13.6 million for fiscal 2025, compared to a net loss of [previous year's net loss, if available] in the prior year, indicating continued unprofitability. Net revenue for fiscal 2025 was $66.4 million, driven by strong performance in the ADHD and Pediatric portfolios, with the Pediatric Portfolio showing a 20% growth. The company has strategically divested its Consumer Health business and is focusing on the commercialization of EXXUA, a significant new product launch anticipated in Q4 2025, which represents a shift in strategy from prior periods.

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share AYTU The Nasdaq Capital M
• $1.70 — sed on the last reported sales price of $1.70 as quoted on the Nasdaq Capital Market
• $22 billion — of therapeutics to compete in the over $22 billion United States prescription MDD market.
• $13.6 million — year since inception. Our net loss was $13.6 million for the year ended June 30, 2025, and a
• $333.5 million — 2025, we had an accumulated deficit of $333.5 million. We expect to continue to incur signifi
• $66.4 million — fiscal 2025, we recorded net revenue of $66.4 million. During the year, we were able to conti
• $57.6 million — on of ADHD product supply, resulting in $57.6 million of net revenue for our ADHD Portfolio,
• $8.8 m — also saw Pediatric Portfolio growth to $8.8 million, a 20% increase from fiscal 2024,
• $16.6 million — June 2025, we raised gross proceeds of $16.6 million from the issuance of (i) 2,806,688 shar
• $1.50 — on stock, at a public offering price of $1.50 and 8,233,332 prefunded warrants at a p
• $1.4999 — warrants at a public offering price of $1.4999 to purchase 8,233,332 shares of our com
• $14.8 million — 2025 Prefunded Warrants"). We received $14.8 million in proceeds net of underwriting commiss
• $1.59 — ur common stock at an exercise price of $1.59 (the "Tranche B Warrants") were exercis
• $3.5 million — were exercised, generating proceeds of $3.5 million. The Tranche B Warrants were converted
• $15.0 million — ortion of these proceeds as part of the $15.0 million term loan repayment described below. E

Filing Documents

• aytu20250630c_10k.htm (10-K) — 2258KB
• ex_848258.htm (EX-10.24) — 239KB
• ex_820735.htm (EX-21.1) — 5KB
• ex_820736.htm (EX-23.1) — 2KB
• ex_820737.htm (EX-31.1) — 13KB
• ex_820738.htm (EX-31.2) — 13KB
• ex_820739.htm (EX-32.1) — 8KB
• aytu20250630c_10kimg001.jpg (GRAPHIC) — 2KB
• 0001437749-25-029723.txt ( ) — 12201KB
• aytu-20250630.xsd (EX-101.SCH) — 109KB
• aytu-20250630_cal.xml (EX-101.CAL) — 84KB
• aytu-20250630_def.xml (EX-101.DEF) — 701KB
• aytu-20250630_lab.xml (EX-101.LAB) — 639KB
• aytu-20250630_pre.xml (EX-101.PRE) — 763KB
• aytu20250630c_10k_htm.xml (XML) — 2089KB

Business

Business 6 Item 1A.

Risk Factors

Risk Factors 18 Item 1B. Unresolved Staff Comments 43 Item 1C. Cybersecurity 44 Item 2.

Properties

Properties 45 Item 3.

Legal Proceedings

Legal Proceedings 45 Item 4. Mine Safety Disclosures 45 PART II 46 Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 46 Item 6. [Reserved] 47 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 47 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 57 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 58 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 98 Item 9A.

Controls and Procedures

Controls and Procedures 98 Item 9B. Other Information 99 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 99 PART III 100 Item 10. Directors, Executive Officers and Corporate Governance 100 Item 11.

Executive Compensation

Executive Compensation 100 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 100 Item 13. Certain Relationships and Related Transactions, and Director Independence 100 Item 14. Principal Accountant Fees and Services 100 PART IV 101 Item 15. Exhibits and Financial Statement Schedules 101 Item 16. Form 10–K Summary 105

SIGNATURES

SIGNATURES 106 2 Table of Contents CAUTIONARY INFORMATION REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K for the year ended June 30, 2025, ("Form 10-K" or "Annual Report"), includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements other than statements of historical facts contained in this Annual Report, including statements regarding our anticipated regulatory events, future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such as "may," "will," "should," "forecast," "could," "expect," "suggest," "believe," "estimate," "continue," "anticipate," "intend," "plan," "potential," or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. Such forward-looking statements include, without limitation, statements regarding the markets for our approved products and our plans for our approved products, the anticipated start dates, durations and completion dates, as well as the potential future results, of our ongoing and future clinical trials, the anticipated designs of our future clinical trials, anticipated future regulatory submissions and events, the potential future commercialization of our product candidates, our anticipated future cash position and future events under our current and potential future collaborations. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including without limitation the risks described in Part I, Item 1A, Risk Factors below and elsewhere in this Annual Report. These risks are not exhaustive. Other sections of this Annual Report include additional factors th

BUSINESS

ITEM 1. BUSINESS Company Overview Aytu BioPharma, Inc. ("Aytu," the "Company," "we," "us," or "our") is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. We were originally incorporated as Rosewind Corporation on August 9, 2002, in the state of Colorado and re-incorporated as Aytu BioScience, Inc. in the state of Delaware on June 8, 2015. In March 2021, we changed our name to Aytu BioPharma, Inc. Our common stock trades on the Nasdaq Capital Market LLC (the "Nasdaq") under the ticker symbol "AYTU." Our principal office is located at 7900 East Union Avenue, Suite 920, Denver, Colorado 80237, and our telephone number is (720) 437-6580. Our strategy is to become a leading pharmaceutical company that improves the lives of patients. We use a focused approach of in-licensing, acquiring, developing and commercializing novel prescription therapeutics in order to continue building our portfolio of revenue-generating products and leveraging our commercial team's expertise to build leading brands within large therapeutic markets. In June 2025, we entered into an Exclusive Commercialization Agreement (the "Commercialization Agreement") with Fabre-Kramer Holdings, Inc. ("Fabre-Kramer") to commercialize EXXUA (gepirone) extended-release tablets ("EXXUA") in the United States. Gepirone is a new chemical entity, and we believe EXXUA to be a novel first-in-class selective serotonin 5HT1a receptor agonist approved by the United States Food and Drug Administration ("FDA") for the treatment of major depressive disorder ("MDD") in adults. EXXUA has been extensively studied in over 5,000 patients and represents a new class of therapeutics to compete in the over $22 billion United States prescription MDD market. We believe it can become a very important treatment option for the estimated 21 million Americans affected by MDD. Over 340 million antidepressant prescriptions were wri

View Full Filing

View this 10-K filing on SEC EDGAR